[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1122947T1 - Στερεη μορφη δοσολογιας που περιλαμβανει μικρονισμενη κυτισινη - Google Patents

Στερεη μορφη δοσολογιας που περιλαμβανει μικρονισμενη κυτισινη

Info

Publication number
CY1122947T1
CY1122947T1 CY20201100355T CY201100355T CY1122947T1 CY 1122947 T1 CY1122947 T1 CY 1122947T1 CY 20201100355 T CY20201100355 T CY 20201100355T CY 201100355 T CY201100355 T CY 201100355T CY 1122947 T1 CY1122947 T1 CY 1122947T1
Authority
CY
Cyprus
Prior art keywords
dosage form
solid dosage
cyticin
form containing
containing micronized
Prior art date
Application number
CY20201100355T
Other languages
English (en)
Inventor
Hanna WAHL
Marek Dabrowa
Piotr Kulazinski
Original Assignee
Aflofarm Farmacja Polska Sp. Z O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50730669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122947(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aflofarm Farmacja Polska Sp. Z O.O. filed Critical Aflofarm Farmacja Polska Sp. Z O.O.
Publication of CY1122947T1 publication Critical patent/CY1122947T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Το αντικείμενο της παρούσας εφεύρεσης είναι στερεή μορφή δοσολογίας που περιέχει κυτισίνη και βοηθητικές ουσίες χαρακτηριζόμενη από το ότι περιέχει από 0,1% έως 5% μικρονισμένη κυτισίνη, όπου όλα τα μόρια έχουν μία διάμετρο μικρότερη από 10 μm, άμυλο αραβοσίτου από 40% έως 60 %, κατά προτίμηση 99,9% σωματίδια μεγέθους από 5 μm έως 25 μm, μακροκρυσταλλική κυτταρίνη σε μία ποσότητα από 40% έως 60%, κατά προτίμηση το μέγεθος σωματιδίων είναι: 99% κάτω από 38 μm, όπου ο λόγος μάζας βοηθητικών ουσιών προς το δραστικό συστατικό είναι από 1:19 έως 1: 999 και είναι στη μορφή μιας σκληρής κάψουλας καθώς και μία μέθοδος λήψης της.
CY20201100355T 2012-11-19 2020-04-15 Στερεη μορφη δοσολογιας που περιλαμβανει μικρονισμενη κυτισινη CY1122947T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL401676A PL220354B1 (pl) 2012-11-19 2012-11-19 Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania
PCT/IB2013/060230 WO2014076680A1 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine

Publications (1)

Publication Number Publication Date
CY1122947T1 true CY1122947T1 (el) 2021-10-29

Family

ID=50730669

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100355T CY1122947T1 (el) 2012-11-19 2020-04-15 Στερεη μορφη δοσολογιας που περιλαμβανει μικρονισμενη κυτισινη

Country Status (16)

Country Link
US (1) US9387172B2 (el)
EP (1) EP2919761B1 (el)
AU (1) AU2013346363B2 (el)
CL (1) CL2015001343A1 (el)
CY (1) CY1122947T1 (el)
DK (1) DK2919761T3 (el)
ES (1) ES2793527T3 (el)
HR (1) HRP20200642T1 (el)
HU (1) HUE048912T2 (el)
LT (1) LT2919761T (el)
NZ (1) NZ708199A (el)
PL (1) PL220354B1 (el)
PT (1) PT2919761T (el)
RS (1) RS60249B1 (el)
SI (1) SI2919761T1 (el)
WO (1) WO2014076680A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL408608A1 (pl) 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CN111278826A (zh) * 2017-07-24 2020-06-12 英国雅琪制药有限公司 野靛碱盐
EP3598968A1 (en) 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
EP4002389A1 (en) 2020-11-17 2022-05-25 TRUMPF Medizin Systeme GmbH + Co. KG Operating room control and communication system
PL444090A1 (pl) * 2023-03-16 2024-09-23 Uniwersytet Rzeszowski Polimerowe kompozycje z cytyzyną oraz sposób ich wytwarzania

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
PT2361081T (pt) 2008-10-14 2016-09-05 Mcneil Ab Forma de dosagem intra-oral multiporção e seu uso
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties

Also Published As

Publication number Publication date
US20150342884A1 (en) 2015-12-03
US9387172B2 (en) 2016-07-12
PL401676A1 (pl) 2014-05-26
AU2013346363B2 (en) 2018-08-09
EP2919761B1 (en) 2020-01-15
HRP20200642T1 (hr) 2020-09-04
ES2793527T3 (es) 2020-11-16
LT2919761T (lt) 2020-05-25
HUE048912T2 (hu) 2020-08-28
EP2919761A1 (en) 2015-09-23
DK2919761T3 (da) 2020-11-02
NZ708199A (en) 2018-10-26
PL220354B1 (pl) 2015-10-30
CL2015001343A1 (es) 2015-10-23
RS60249B1 (sr) 2020-06-30
PT2919761T (pt) 2020-05-18
AU2013346363A1 (en) 2015-06-11
SI2919761T1 (sl) 2020-08-31
WO2014076680A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
CY1122947T1 (el) Στερεη μορφη δοσολογιας που περιλαμβανει μικρονισμενη κυτισινη
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EA201690541A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
BR112014029206A2 (pt) pós hemostáticos de celulose regenerada oxidada e métodos para fabricação dos mesmos
MX2016003660A (es) Conjugados de partícula similar a virus para el diagnóstico y tratamiento de tumores.
UA112540C2 (uk) Плівкова лікарська форма, яка містить вільну основу силденафілу, і спосіб її отримання
EA201390079A1 (ru) Пероральная лекарственная форма деферазирокса
PH12015502535A1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
CY1124635T1 (el) Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
CY1120185T1 (el) Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης
IN2014DN09940A (el)
BR112014030160A2 (pt) composição formadora de película, uso de uma composição formadora de película, película e cápsula dura
CY1121986T1 (el) Στερεη φαρμακευτικη συνθεση κυtισινης και διαδικασια για την παρασκευη της
EA201401151A1 (ru) Способы получения гидрохлорида анаморелина с контролируемым содержанием хлора
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
WO2014043243A3 (en) Platinum compounds, compositions and methods for the treatment of cancer
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
EA201792563A1 (ru) Исходный материал для напитка
WO2014122671A3 (en) Solid oral compositions of saxagliptin
JP2013079218A5 (el)